Design of ALTA-1L (ALK in lung cancer trial of brigatinib in first-line), a randomized phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

Authors
Category Systematic review
JournalJournal of Clinical Oncology
Year 2017
This article has no abstract
Epistemonikos ID: 0add62ab589f865ab85eec558158df2c978844ec
First added on: Feb 08, 2025